Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Cytokinetics Inc., profitability ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Return on Sales
Operating profit margin -6,344.43% -4,843.18% -378.18% -342.75% -147.66% -118.84% -343.79% -264.54% -932.79% -219.08% -177.95% -168.27% -149.57% -590.60% -471.06% -367.97% -311.34% -254.38% -251.62% -282.26%
Net profit margin -6,739.96% -5,422.19% -439.35% -411.21% -190.34% -142.85% -396.22% -305.72% -1,061.13% -269.48% -230.55% -228.00% -209.88% -751.39% -592.61% -452.93% -378.69% -308.72% -303.70% -337.41%
Return on Investment
Return on equity (ROE) -193.80% -221.62% -88.29% -91.83% -944.65% -198.96% -112.27% -76.20% -3,124.97% -409.84%
Return on assets (ROA) -71.12% -69.19% -48.41% -38.33% -26.22% -27.98% -30.09% -25.59% -27.63% -27.60% -23.39% -23.85% -24.04% -60.39% -51.34% -41.99% -62.71% -55.48% -53.06% -50.33%

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Cytokinetics Inc. operating profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Cytokinetics Inc. net profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Cytokinetics Inc. ROA deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Operating Profit Margin

Cytokinetics Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Operating income (loss) (122,265) (122,049) (124,473) (127,030) (108,441) (10,874) (77,857) (21,704) (69,201) (54,797) (40,611) (36,407) 5,184 (32,358) (30,362) (23,706) (23,927) (26,716) (24,518) (21,458) (17,914) (23,413) (26,131)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Profitability Ratio
Operating profit margin1 -6,344.43% -4,843.18% -378.18% -342.75% -147.66% -118.84% -343.79% -264.54% -932.79% -219.08% -177.95% -168.27% -149.57% -590.60% -471.06% -367.97% -311.34% -254.38% -251.62% -282.26%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 27.32% 31.03% 28.49% 31.21% 30.59% 30.33% 32.68% 31.89% 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03%
Amgen Inc. 34.55% 37.50% 36.07% 38.57% 39.31% 38.04% 32.78% 31.44% 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57%
Bristol-Myers Squibb Co. 16.96% 17.29% 18.13% 17.96% 19.04% 18.19% 16.79% 15.91% -15.73% -17.02% -19.19% -21.60% 9.27% 11.67% 16.30% 22.62%
Danaher Corp. 23.83% 25.06% 27.02% 27.61% 27.35% 25.44% 25.23% 25.35% 24.63% 25.04% 22.30% 18.99% 17.61% 17.37% 18.01% 18.25%
Eli Lilly & Co. 18.42% 24.17% 22.45% 24.97% 24.65% 25.50% 25.94% 22.45% 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29%
Gilead Sciences Inc. 30.37% 31.18% 33.03% 27.17% 22.39% 25.78% 26.56% 36.72% 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Johnson & Johnson 25.55% 25.61% 25.21% 24.63% 23.89% 23.47% 23.76% 24.95% 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15%
Merck & Co. Inc. 13.08% 10.34% 27.85% 30.27% 30.66% 33.04% 28.85% 25.74% 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77%
Moderna Inc. -30.50% 5.08% 33.67% 51.10% 64.60% 70.46% 74.34% 75.22% 69.57% 62.28% 32.79% -381.82%
Pfizer Inc. 14.36% 28.13% 34.44% 34.83% 33.59% 30.37% 26.12% 23.91% 24.67% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46%
Regeneron Pharmaceuticals Inc. 32.23% 34.20% 35.79% 38.93% 45.45% 48.19% 55.08% 55.67% 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Thermo Fisher Scientific Inc. 15.81% 15.42% 16.29% 18.69% 20.54% 22.51% 23.83% 25.57% 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99%

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Operating profit margin = 100 × (Operating income (loss)Q3 2023 + Operating income (loss)Q2 2023 + Operating income (loss)Q1 2023 + Operating income (loss)Q4 2022) ÷ (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022)
= 100 × (-122,265 + -122,049 + -124,473 + -127,030) ÷ (378 + 867 + 4,613 + 1,957) = -6,344.43%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Cytokinetics Inc. operating profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Net Profit Margin

Cytokinetics Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Revenues 378 867 4,613 1,957 2,515 88,968 1,148 55,600 5,437 2,843 6,548 6,722 41,688 3,593 3,825 5,212 6,055 7,137 8,464 9,377 10,641 6,215 5,268
Profitability Ratio
Net profit margin1 -6,739.96% -5,422.19% -439.35% -411.21% -190.34% -142.85% -396.22% -305.72% -1,061.13% -269.48% -230.55% -228.00% -209.88% -751.39% -592.61% -452.93% -378.69% -308.72% -303.70% -337.41%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 11.81% 15.50% 13.37% 20.39% 23.19% 22.04% 22.00% 20.54% 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69%
Amgen Inc. 29.52% 31.52% 31.77% 26.42% 27.88% 26.73% 23.42% 24.25% 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32%
Bristol-Myers Squibb Co. 18.44% 17.62% 15.95% 13.71% 14.29% 14.04% 13.31% 15.08% -11.89% -11.44% -14.53% -21.20% -0.11% -1.61% 3.08% 13.15%
Danaher Corp. 22.89% 22.80% 23.32% 22.91% 21.65% 20.61% 21.32% 21.84% 20.97% 21.00% 19.17% 16.36% 18.05% 18.35% 18.13% 16.80%
Eli Lilly & Co. 15.55% 22.01% 20.54% 21.88% 20.63% 19.58% 20.90% 19.71% 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27%
Gilead Sciences Inc. 21.60% 20.18% 20.87% 17.02% 12.44% 15.22% 16.60% 23.05% 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Johnson & Johnson 39.58% 14.52% 13.77% 18.90% 19.95% 19.21% 20.90% 22.26% 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42%
Merck & Co. Inc. 7.77% 5.34% 22.52% 24.49% 25.88% 29.00% 26.27% 26.79% 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01%
Moderna Inc. -39.67% 11.95% 33.37% 45.36% 57.36% 63.31% 66.94% 69.04% 64.55% 57.01% 30.95% -373.77%
Pfizer Inc. 15.13% 27.38% 31.19% 31.27% 29.81% 28.94% 27.01% 27.04% 28.77% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45%
Regeneron Pharmaceuticals Inc. 30.47% 33.93% 33.81% 35.64% 39.17% 39.97% 48.06% 50.25% 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Thermo Fisher Scientific Inc. 13.68% 13.14% 13.75% 15.47% 15.92% 17.37% 18.49% 19.70% 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47%

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Net profit margin = 100 × (Net lossQ3 2023 + Net lossQ2 2023 + Net lossQ1 2023 + Net lossQ4 2022) ÷ (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022)
= 100 × (-129,422 + -128,637 + -131,289 + -137,380) ÷ (378 + 867 + 4,613 + 1,957) = -6,739.96%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Cytokinetics Inc. net profit margin ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Return on Equity (ROE)

Cytokinetics Inc., ROE calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Stockholders’ equity (deficit) (438,801) (333,115) (229,020) (107,900) (15,977) 111,414 116,261 243,863 249,020 16,489 67,846 113,383 149,605 (78,080) (45,711) (10,937) (19,869) (4,896) 3,372 25,934 52,069 75,170 99,599
Profitability Ratio
ROE1 -193.80% -221.62% -88.29% -91.83% -944.65% -198.96% -112.27% -76.20% -3,124.97% -409.84%
Benchmarks
ROE, Competitors2
AbbVie Inc. 53.86% 67.50% 57.14% 68.60% 83.83% 86.24% 76.64% 74.91% 55.60% 53.01% 37.63% 35.30% 48.34% 47.30%
Amgen Inc. 98.82% 117.67% 148.04% 178.97% 187.11% 271.85% 624.78% 87.96% 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07%
Bristol-Myers Squibb Co. 28.57% 24.91% 22.97% 20.37% 20.44% 20.30% 19.79% 19.46% -14.52% -13.80% -16.54% -23.84% -0.09% -1.15% 1.91% 6.66%
Danaher Corp. 11.29% 12.30% 13.47% 14.39% 14.40% 13.63% 13.93% 14.24% 13.54% 13.12% 11.76% 9.17% 9.70% 9.56% 10.53% 9.94%
Eli Lilly & Co. 44.46% 58.73% 50.82% 58.64% 59.91% 66.61% 65.69% 62.16% 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09%
Gilead Sciences Inc. 26.33% 25.92% 26.59% 21.62% 15.82% 20.44% 22.66% 29.55% 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Johnson & Johnson 48.61% 17.37% 17.95% 23.36% 25.68% 24.05% 26.54% 28.20% 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42%
Merck & Co. Inc. 11.17% 8.04% 27.82% 31.57% 34.32% 38.34% 34.68% 34.17% 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99%
Moderna Inc. -25.76% 7.12% 25.36% 43.73% 65.39% 78.15% 85.73% 86.26% 69.75% 52.13% 15.59% -29.17% -21.66% -16.54% -30.82% -43.75%
Pfizer Inc. 10.81% 21.68% 28.77% 32.79% 32.14% 33.61% 30.29% 28.47% 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77%
Regeneron Pharmaceuticals Inc. 16.03% 17.90% 17.80% 19.14% 25.05% 27.49% 39.84% 43.03% 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Thermo Fisher Scientific Inc. 13.11% 13.08% 14.26% 15.80% 16.15% 17.59% 18.56% 18.94% 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45%

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
ROE = 100 × (Net lossQ3 2023 + Net lossQ2 2023 + Net lossQ1 2023 + Net lossQ4 2022) ÷ Stockholders’ equity (deficit)
= 100 × (-129,422 + -128,637 + -131,289 + -137,380) ÷ -438,801 =

2 Click competitor name to see calculations.


Return on Assets (ROA)

Cytokinetics Inc., ROA calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in thousands)
Net loss (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Total assets 740,614 779,899 889,815 1,014,775 1,075,961 771,717 856,253 841,319 827,539 564,302 577,062 533,803 474,112 232,495 256,582 289,814 187,393 198,218 198,611 211,178 230,279 247,239 279,926
Profitability Ratio
ROA1 -71.12% -69.19% -48.41% -38.33% -26.22% -27.98% -30.09% -25.59% -27.63% -27.60% -23.39% -23.85% -24.04% -60.39% -51.34% -41.99% -62.71% -55.48% -53.06% -50.33%
Benchmarks
ROA, Competitors2
AbbVie Inc. 4.78% 6.42% 5.64% 8.53% 9.49% 8.83% 8.71% 7.88% 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84%
Amgen Inc. 8.36% 8.84% 8.92% 10.06% 10.73% 11.09% 9.67% 9.63% 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13%
Bristol-Myers Squibb Co. 9.08% 8.52% 7.75% 6.53% 6.80% 6.59% 6.07% 6.40% -4.87% -4.58% -5.53% -7.61% -0.04% -0.44% 0.74% 2.65%
Danaher Corp. 6.74% 7.49% 8.15% 8.55% 8.35% 7.76% 7.74% 7.73% 7.13% 7.19% 6.30% 4.79% 5.05% 4.86% 4.74% 4.85%
Eli Lilly & Co. 8.61% 11.85% 10.70% 12.62% 12.71% 12.09% 13.06% 11.44% 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17%
Gilead Sciences Inc. 9.42% 8.80% 9.02% 7.27% 5.33% 6.58% 7.16% 9.16% 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%
Johnson & Johnson 20.85% 6.81% 6.49% 9.57% 10.94% 10.33% 11.12% 11.47% 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59%
Merck & Co. Inc. 4.32% 2.98% 12.09% 13.30% 14.25% 15.48% 13.29% 12.35% 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66%
Moderna Inc. -17.82% 5.52% 19.83% 32.34% 45.15% 53.97% 53.02% 49.46% 33.75% 21.64% 4.71% -10.18% -12.85% -13.98% -24.46% -32.34%
Pfizer Inc. 4.87% 9.75% 14.85% 15.91% 15.32% 15.01% 13.58% 12.11% 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72%
Regeneron Pharmaceuticals Inc. 12.41% 14.02% 13.91% 14.85% 19.40% 20.90% 30.11% 31.75% 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%
Thermo Fisher Scientific Inc. 6.12% 6.08% 6.36% 7.15% 7.77% 8.21% 8.20% 8.12% 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33%

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
ROA = 100 × (Net lossQ3 2023 + Net lossQ2 2023 + Net lossQ1 2023 + Net lossQ4 2022) ÷ Total assets
= 100 × (-129,422 + -128,637 + -131,289 + -137,380) ÷ 740,614 = -71.12%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Cytokinetics Inc. ROA deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.